Key Investor Signals
Up to €1.5M in SPRIND non-dilutive funding
SPRIND selected MoleSense for its Continuous Hormone Monitoring Challenge, providing access to up to €1.5M in non-dilutive funding for sensor development.
Patch advanced into patient testing with obstetrics specialists
MoleSense advanced the patch into patient testing with obstetrics specialists in Lausanne, assessing comfort and practical use ahead of biomarker validation.
MoleSense joined an Innosuisse project with EPFL, CSEM and CHUV
The Innosuisse-backed project brought MoleSense together with EPFL, CSEM and CHUV, combining sensor engineering, translational research and clinical expertise.
Other Positive Signals
- Raised approximately CHF 1.5M in grants, non-dilutive funding and convertible loans
- Won the 2025 Swiss Innovation Challenge.
- Secured a CHF 100,000 FIT Tech Seed loan in 2026, alongside strategic and technical support from CSEM.
- Selected for Venture Leaders Medtech 2026 and the Swiss National Startup Team roadshow to Boston.
- Won a 2026 Swiss Product Award for its biosensor wearable patch.
Team
Gian Luca Barbruni
CEO and Co-founder
- PhD in Microelectronics and Microsystems from EPFL, focused on ultra-miniaturised wireless implantable bioelectronics.
- Postdoctoral scientist and Sciencepreneur at EPFL from 2023 to 2026, working on low-power sensing circuits and micro-scale bioelectronics.
- Named inventor on EPFL patent applications covering wireless power for multiple implants and implant microelectrodes.
Ata Golparvar
CTO and Co-founder
- PhD in Microsystems and Microelectronics from EPFL, focused on wearable electrochemical sensing systems.
- Developed the core sweat-sensing technology behind MoleSense during his doctoral research at EPFL.
- Published research on wearable lactate and urea sensing in Sensors and Actuators B in 2023.
Product
MoleSense is developing Wear & Forget, a needle-free patch that collects sweat on demand and measures hormones and inflammatory biomarkers. The platform is designed for repeated molecular monitoring across fertility, pregnancy and postpartum care.
On-demand sweat collection
The patch stimulates and collects small sweat samples when a reading is required, including at rest. Microfluidic channels route the sample through the patch, removing the need for exercise or natural sweating.
Targeted molecular sensing
The sensing layer uses short DNA strands designed to bind specific hormones and inflammatory proteins. Each binding event is converted into an electronic signal that can be measured by the patch.
Individual trend monitoring
Software tracks each wearer’s readings over time and identifies changes relative to their individual baseline. Low-power electronics support repeated measurements and wireless data transmission.
Market Overview
High-risk pregnancies require closer surveillance because complications can emerge between routine appointments. Current care still relies heavily on clinic visits, blood tests and point-in-time measurements, creating demand for less invasive technologies that can track molecular changes more frequently.
MoleSense addresses two established device markets: fetal monitoring and fertility monitoring. Together, these categories represent billions of dollars in annual spending, while continuous hormone sensing could extend monitoring across fertility, pregnancy and postpartum care.
Share of pregnancies in Switzerland classified as high-risk and requiring closer monitoring.
Babies born before 37 weeks in 2020, equivalent to more than one in ten births worldwide.
Estimated global market for fetal monitoring devices, consumables and related monitoring technologies.
Estimated global market for fertility monitoring technologies, including connected and at-home devices.
Comparable Outcomes
Preventice Solutions
Preventice Solutions developed wearable cardiac monitors and remote monitoring services that detected irregular heart rhythms outside the hospital setting. Boston Scientific acquired Preventice Solutions in March 2021 for up to $1.225B.
Modern Fertility
Modern Fertility developed at-home hormone testing for reproductive health and ovarian reserve, later expanding into ovulation, pregnancy and cycle-tracking products. Ro acquired Modern Fertility in May 2021 for a reported value of more than $225M.
Interested in More Startups Like MoleSense?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.